[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100202154":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":30,"centralContacts":23,"locations":34,"responsibleParty":67,"collaborators":23,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":23,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":23,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":23,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1, low dose","EXPERIMENTAL","ABT-354",[13,14],"Drug: ABT-354","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Group 2, high dose",[13,14],[19,24,27],{"type":20,"name":11,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","ABT-354 Low Dose",[9],null,{"type":20,"name":11,"description":25,"armGroupLabels":26,"otherNames":23},"ABT-354 High Dose",[16],{"type":20,"name":28,"description":28,"armGroupLabels":29,"otherNames":23},"Placebo",[9,16],[31],{"name":32,"affiliation":5,"role":33},"Gerard Marek, MD","STUDY_DIRECTOR",[35,48,57],{"facility":36,"status":23,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":23},"Site Reference ID\u002FInvestigator# 106999","Miami","Florida","33169","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-80.19366,25.77427,{"lat":46,"lon":45},{"facility":49,"status":23,"city":50,"state":38,"zip":51,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":23},"Site Reference ID\u002FInvestigator# 106998","Orlando","32806",{"type":43,"coordinates":53},[54,55],-81.37924,28.53834,{"lat":55,"lon":54},{"facility":58,"status":23,"city":59,"state":60,"zip":61,"country":40,"countryCode":41,"cosmosGeoPoint":62,"geoPoint":66,"contacts":23},"Site Reference ID\u002FInvestigator# 107000","Overland Park","Kansas","66212",{"type":43,"coordinates":63},[64,65],-94.67079,38.98223,{"lat":65,"lon":64},{"type":68,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100202154","phase-1-safety-tolerability-and-pharmacokinetics-of-abt-354-in-subjects-with-mild-to-moderate-alzheimers-disease-on-stable-doses-of-acetylcholinesterase-inhibitors-100202154",false,"NCT01908010","Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","Inclusion Criteria:\n\n* Meets the National Institute of Neurological and Communicative Disorders and Stroke\u002FAlzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's Disease\n* Has a Mini-Mental State Examination total score of 16 to 26, inclusive, at Screening\n* Has a Modified Hachinski Ischemia Scale score of ≤ 4 at Screening\n* On a stable dose of - donepezil, galantamine or rivastigmine for at least 30 days prior to study drug administration\n* Has had a computerized tomography or magnetic resonance imaging scan, interpreted by a radiologist or neurologist, within 36 months prior to randomization\n\nExclusion Criteria:\n\n* Receipt of any depot drug by injection within 30 days prior to study drug administration\n* Receipt of an investigational product within a time period equal to 10 half-lives, if known, or within 6 weeks prior to study drug administration\n* History of any significant neurological disease other than Alzheimer's Disease\n* History of significant sensitivity or allergy to multiple drugs based on medical records and\u002For the opinion of the investigator\n* Significant current - suicidal ideation within 1 month prior to study drug administration as evidenced by answering \"yes\" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale completed at Screening or any history of suicide attempts","ALL","55 Years","90 Years",{"count":80,"type":81},20,"ACTUAL","INTERVENTIONAL",[84],"PHASE1","This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.",[87],"Alzheimer's Disease",[89],"Alzheimer's disease","COMPLETED","2013-12-09",{"date":93,"type":94},"2013-12-11","ESTIMATED",{"date":96,"type":23},"2013-07",{"date":98,"type":81},"2013-11",{"name":5,"class":6},3]